The Epidemiology of Antibiotic-Related Adverse Events in the Treatment of Diabetic Foot Infections: A Narrative Review of the Literature

The use of antibiotics for the treatment of diabetic foot infections (DFIs) over an extended period of time has been shown to be associated with adverse events (AEs), whereas interactions with concomitant patient medications must also be considered. The objective of this narrative review was to summ...

Descripción completa

Detalles Bibliográficos
Autores: Soldevila-Boixader, Laura, Murillo Rubio, Óscar, Waibel, Felix W. A., Huber, Tanja, Schöni, Madlaina, Lalji, Rahim, Uçkay, Ilker
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2023
País:España
Institución:Universidad de Barcelona
Repositorio:Dipòsit Digital de la UB
OAI Identifier:oai:diposit.ub.edu:2445/198592
Acceso en línea:https://hdl.handle.net/2445/198592
Access Level:acceso abierto
Palabra clave:Antibiòtics
Peu diabètic
Antibiotics
Diabetic foot
id ES_d24501007d70566b6063b10e58eef4e0
oai_identifier_str oai:diposit.ub.edu:2445/198592
network_acronym_str ES
network_name_str España
repository_id_str
spelling The Epidemiology of Antibiotic-Related Adverse Events in the Treatment of Diabetic Foot Infections: A Narrative Review of the LiteratureSoldevila-Boixader, LauraMurillo Rubio, ÓscarWaibel, Felix W. A.Huber, TanjaSchöni, MadlainaLalji, RahimUçkay, IlkerAntibiòticsPeu diabèticAntibioticsDiabetic footThe use of antibiotics for the treatment of diabetic foot infections (DFIs) over an extended period of time has been shown to be associated with adverse events (AEs), whereas interactions with concomitant patient medications must also be considered. The objective of this narrative review was to summarize the most frequent and most severe AEs reported in prospective trials and observational studies at the global level in DFI. Gastrointestinal intolerances were the most frequent AEs, from 5% to 22% among all therapies; this was more common when prolonged antibiotic administration was combined with oral beta-lactam or clindamycin or a higher dose of tetracyclines. The proportion of symptomatic colitis due to Clostridium difficile was variable depending on the antibiotic used (0.5% to 8%). Noteworthy serious AEs included hepatotoxicity due to beta-lactams (5% to 17%) or quinolones (3%); cytopenia's related to linezolid (5%) and beta-lactams (6%); nausea under rifampicin, and renal failure under cotrimoxazole. Skin rash was found to rarely occur and was commonly associated with the use of penicillins or cotrimoxazole. AEs from prolonged antibiotic use in patients with DFI are costly in terms of longer hospitalization or additional monitoring care and can trigger additional investigations. The best way to prevent AEs is to keep the duration of antibiotic treatment short and with the lowest dose clinically necessary.MDPI AG2023info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://hdl.handle.net/2445/198592Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))reponame:Dipòsit Digital de la UBinstname:Universidad de BarcelonaInglésReproducció del document publicat a: https://doi.org/10.3390/antibiotics12040774Antibiotics, 2023, vol. 12, num. 4https://doi.org/10.3390/antibiotics12040774cc by (c) Soldevila Boixader, Laura et al, 2023http://creativecommons.org/licenses/by/3.0/es/info:eu-repo/semantics/openAccessoai:diposit.ub.edu:2445/1985922026-05-27T06:46:51Z
dc.title.none.fl_str_mv The Epidemiology of Antibiotic-Related Adverse Events in the Treatment of Diabetic Foot Infections: A Narrative Review of the Literature
title The Epidemiology of Antibiotic-Related Adverse Events in the Treatment of Diabetic Foot Infections: A Narrative Review of the Literature
spellingShingle The Epidemiology of Antibiotic-Related Adverse Events in the Treatment of Diabetic Foot Infections: A Narrative Review of the Literature
Soldevila-Boixader, Laura
Antibiòtics
Peu diabètic
Antibiotics
Diabetic foot
title_short The Epidemiology of Antibiotic-Related Adverse Events in the Treatment of Diabetic Foot Infections: A Narrative Review of the Literature
title_full The Epidemiology of Antibiotic-Related Adverse Events in the Treatment of Diabetic Foot Infections: A Narrative Review of the Literature
title_fullStr The Epidemiology of Antibiotic-Related Adverse Events in the Treatment of Diabetic Foot Infections: A Narrative Review of the Literature
title_full_unstemmed The Epidemiology of Antibiotic-Related Adverse Events in the Treatment of Diabetic Foot Infections: A Narrative Review of the Literature
title_sort The Epidemiology of Antibiotic-Related Adverse Events in the Treatment of Diabetic Foot Infections: A Narrative Review of the Literature
dc.creator.none.fl_str_mv Soldevila-Boixader, Laura
Murillo Rubio, Óscar
Waibel, Felix W. A.
Huber, Tanja
Schöni, Madlaina
Lalji, Rahim
Uçkay, Ilker
author Soldevila-Boixader, Laura
author_facet Soldevila-Boixader, Laura
Murillo Rubio, Óscar
Waibel, Felix W. A.
Huber, Tanja
Schöni, Madlaina
Lalji, Rahim
Uçkay, Ilker
author_role author
author2 Murillo Rubio, Óscar
Waibel, Felix W. A.
Huber, Tanja
Schöni, Madlaina
Lalji, Rahim
Uçkay, Ilker
author2_role author
author
author
author
author
author
dc.subject.none.fl_str_mv Antibiòtics
Peu diabètic
Antibiotics
Diabetic foot
topic Antibiòtics
Peu diabètic
Antibiotics
Diabetic foot
description The use of antibiotics for the treatment of diabetic foot infections (DFIs) over an extended period of time has been shown to be associated with adverse events (AEs), whereas interactions with concomitant patient medications must also be considered. The objective of this narrative review was to summarize the most frequent and most severe AEs reported in prospective trials and observational studies at the global level in DFI. Gastrointestinal intolerances were the most frequent AEs, from 5% to 22% among all therapies; this was more common when prolonged antibiotic administration was combined with oral beta-lactam or clindamycin or a higher dose of tetracyclines. The proportion of symptomatic colitis due to Clostridium difficile was variable depending on the antibiotic used (0.5% to 8%). Noteworthy serious AEs included hepatotoxicity due to beta-lactams (5% to 17%) or quinolones (3%); cytopenia's related to linezolid (5%) and beta-lactams (6%); nausea under rifampicin, and renal failure under cotrimoxazole. Skin rash was found to rarely occur and was commonly associated with the use of penicillins or cotrimoxazole. AEs from prolonged antibiotic use in patients with DFI are costly in terms of longer hospitalization or additional monitoring care and can trigger additional investigations. The best way to prevent AEs is to keep the duration of antibiotic treatment short and with the lowest dose clinically necessary.
publishDate 2023
dc.date.none.fl_str_mv 2023
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://hdl.handle.net/2445/198592
url https://hdl.handle.net/2445/198592
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.relation.none.fl_str_mv Reproducció del document publicat a: https://doi.org/10.3390/antibiotics12040774
Antibiotics, 2023, vol. 12, num. 4
https://doi.org/10.3390/antibiotics12040774
dc.rights.none.fl_str_mv cc by (c) Soldevila Boixader, Laura et al, 2023
http://creativecommons.org/licenses/by/3.0/es/
info:eu-repo/semantics/openAccess
rights_invalid_str_mv cc by (c) Soldevila Boixader, Laura et al, 2023
http://creativecommons.org/licenses/by/3.0/es/
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv MDPI AG
publisher.none.fl_str_mv MDPI AG
dc.source.none.fl_str_mv Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))
reponame:Dipòsit Digital de la UB
instname:Universidad de Barcelona
instname_str Universidad de Barcelona
reponame_str Dipòsit Digital de la UB
collection Dipòsit Digital de la UB
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869420335933161472
score 15.301603

Similares en LA Referencia